Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Panel Recommends Label Change for Lilly’s Jardiance

By Stephanie Guzowski | June 29, 2016

A U.S. Food and Drug Administration (FDA) panel on Tuesday voted yes, that the diabetes drug Jardiance, manufactured by Eli Lilly and Boehringer Ingelheim, also reduces the risk of cardiovascular death — and that its label should be updated to include this claim.

The panel’s vote was narrow, coming in at 12 to 11. Next, the FDA will decide whether to follow this recommendation.

The FDA approved Jardiance (empagliflozin), an SGLT2 inhibitor, in 2014 to lower blood sugar in patients with type 2 diabetes.

In January, the companies submitted results from an additional clinical trial, which showed Jardiance cut the combined risk of cardiac death, non-fatal heart attacks and non-fatal strokes by 14 percent. The diabetes drug cut the risk of death from any cause by 32 percent. However, there was no significant difference in the risk of non-fatal heart attack or non-fatal stroke.

Prior to the label change recommendation, the FDA asked advisors to determine if “this single trial provides substantial evidence necessary to establish a new benefit.” Normally efficacy claims require additional trials although there are instances “in which a single adequate and well-controlled study has served as the basis for a claim.”

Jardiance revenue was $38.2 million in Q1, up 99 percent, with nearly $30 million coming from the U.S., according to Lilly.

Other SGLT2 inhibitors on the market include Johnson & Johnson’s Invokana and AstraZeneca’s Farxiga.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE